Rich Rogers discusses his vision of what the future may hold for the multi-attribute method (MAM) in the biopharmaceutical industry

CASE STUDY 73683 Deploying the multi-attribute method (MAM) across sites at Pfizer Pfizer is building the MAM lab-of-the-future Pfizer is a leading research-based biopharmaceutical company. At Pfizer, scientific principles, innovation, and the company’s global resources are applied to bring therapies…

Case study | 001487 Mass spectrometry Multi-Attribute Method (MAM) offers an ideal solution for development and release of safe and effective biotherapeutics Northeastern University Biopharmaceutical Analysis and Training Laboratory (BATL) “I approach drug development with a quality lens. Understanding the…

[ eBOOK ] Multi-Attribute Methods for Biopharmaceutical Analysis Perspectives on the adoption of LC-MS based attribute analysis for biopharmaceuticals [ eBOOK ] Introduction The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly…

TECHNICAL NOTE 73535 Performing the biopharmaceutical multi-attribute method (MAM) Keywords: Multi-attribute method, MAM, HR MAM, BioPharma Finder, Chromeleon Chromatography Data System, CDS, product quality attributes, PQAs, critical quality attributes, CQAs, high resolution, accurate mass, HRAM, compliance Introduction The Multi-Attribute Method…